SCHEMBL4877870

SCHEMBL4877870

CN1CCC(NCCC2CCCN2C(=O)OC(C)(C)C)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.42
KDM1A O60341 1/20 0.41
OPRD1 P41143 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
EPHX1 P07099 1/20 0.40
HSD17B10 Q99714 1/20 0.39
APP P05067 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
SLC6A2 P23975 1/20 0.39
HRH2 P25021 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR7 P34969 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4880675 0.88 KDM1A (0.48) ATMKDM1AOPRD1SMN1; SMN2EPHX1
SCHEMBL11969272 0.84 OPRD1 (0.52) ATMKDM1AOPRD1APPHTR1A
SCHEMBL30511063 0.82 SMN1; SMN2 (0.44) ATMKDM1AOPRD1SMN1; SMN2HSD17B10
SCHEMBL11969924 0.81 KDM1A (0.55) ATMKDM1AOPRD1DRD2NPC1
SCHEMBL23789298 0.80 SMN1; SMN2 (0.43) ATMKDM1AOPRD1SMN1; SMN2HSD17B10
SCHEMBL3251047 0.79 APP (0.51) ATMKDM1AOPRD1SMN1; SMN2EPHX1
SCHEMBL3251277 0.79 APP (0.51) ATMKDM1AOPRD1SMN1; SMN2EPHX1
SCHEMBL4163210 0.79 APP (0.51) ATMKDM1AOPRD1SMN1; SMN2EPHX1
SCHEMBL13202546 0.78 ATM (0.46) ATMKDM1AOPRD1SMN1; SMN2EPHX1
SCHEMBL639097 0.77 ATM (0.49) ATMOPRD1SMN1; SMN2HSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE ATM 371/4885KDM1A 1605/4885OPRD1 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.